Bahram Valamehr, Ph.D.

Bahram Valamehr, Ph.D.

President, Chief Executive Officer and DirectoratFate Therapeutics· In proxies 2022–2025

Pay in FY2025-37% from the year before · Fate Therapeutics stock -40.4% the same year

Bahram Valamehr, Ph.D. was paid $2.2M in FY2025 (Dec), down 37%. Fate Therapeutics stock fell 40.4% that year.

Pay$100 in the stock at the end of FY21 → $2
Pay is from the Summary Compensation Table of each Fate Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Fate TherapeuticsPublic company · 4 yr
    • President, Chief Executive Officer and Director2022 – Present · 4 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?